Please login to order a test.
Myasthenia Gravis Complete Antibody Profile
- Acetylcholine Receptor Complete Antibody Profile
- Myasthenia Gravis Evaluation Complete Profile
Acetylcholine receptor-binding antibody; acetylcholine receptor-blocking antibody; acetylcholine receptor-modulating antibody; striational antibody
Diagnose myasthenia gravis (MG); monitor response to treatment of myasthenia gravis
False positives can occur in patients with serum drawn within 48 hours of administration of general anesthesia and muscle relaxants. Antibodies to alpha-bungarotoxin may sometimes be found in patients treated with snake venom. Recently administered radioisotopes may interfere with the assay in unpredictable ways. Acetylcholine receptor autoantibodies are not typically found in congenital myasthenia gravis.
AChR-blocking antibodies may be considered by Medicare and other carriers as investigational and, therefore, may not be payable as a covered benefit for patients.
AChR-binding assay and blocking antibody: radioimmunoassay (RIA); AChR-modulating antibody: cell culture based radioimmunoassay (RIA); antimuscle (striational antibody): indirect fluorescent antibody (IFA)
Myasthenia gravis is an autoimmune disorder manifested by muscle weakness caused by the loss or dysfunction of acetylcholine receptors (AChR) of skeletal muscle. Autoantibodies (binding, blocking, and/or modulating) to postsynaptic AChRs are detectable in the serum of 90% of patients with generalized MG and in 55% to 70% of patients with ocular myasthenia. These autoantibodies interfere with normal neuromuscular function, causing muscle weakness and fatigue. Receptor antibody levels tend to rise several weeks before symptoms increase in patients with established MG. Remission after thymectomy is associated with a progressive decline in antibody levels. Consequently, measurements of AChR antibodies can be used in monitoring disease progression as well as the effects of treatment. Modulating antibodies are responsible for the degradation of AChR at the muscle cell surface. Modulating antibodies bind to two receptor molecules on the cell surface and accelerate internalization, triggering endocytosis and degradation. The relative increase in this degradation rate closely corresponds to the disease severity.
1 mL (Note: This volume does not allow for repeat testing.)
Separate serum from cells within 45 minutes of collection. Send serum in plastic transport tube.
Causes for Rejection
Improper labeling; gross microbial contamination; specimen contaminated with anticoagulants; chylous serum; plasma specimen
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|086005||Myasthenia Gravis Full Panel||085904||AChR Binding Abs, Serum||nmol/L||11034-6|
|086005||Myasthenia Gravis Full Panel||085927||AChR Blocking Abs, Serum||%||11561-8|
|086005||Myasthenia Gravis Full Panel||085934||AChR Modulating Ab||%||30192-9|
|086005||Myasthenia Gravis Full Panel||161216||Anti-striation Abs||5372-8|